Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Submission of Matters to a Vote of Security Holders. |
On September 13, 2017, at the 2017 Annual Meeting of Stockholders (the “2017 Annual Meeting”) of Repros Therapeutics Inc. (the “Company”), the stockholders of the Company voted on (1) the election of six directors, each to serve until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified, (2) the ratification and approval of the appointment of PricewaterhouseCoopers LLP as the Company’s registered independent public accounting firm for the fiscal year ending December 31, 2017 and (3) an advisory vote to approve, on an advisory basis, the compensation of the Company’s named executive officers. The voting results on these proposals were as follows:
| Proposal 1. |
Election of six directors to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified. |
| Nominee |
Votes For |
Withheld |
Broker Non-Votes |
| Daniel F. Cain |
6,442,589 |
453,485 |
18,939,048 |
| Larry Dillaha, M.D. |
6,412,073 |
484,001 |
18,939,048 |
| Patrick Fourteau |
6,405,155 |
490,919 |
18,939,048 |
| Nola E. Masterson |
6,441,463 |
454,611 |
18,939,048 |
| Saira Ramasastry |
6,394,626 |
501,448 |
18,939,048 |
| Michael G. Wyllie, Ph.D., DSC |
4,524,123 |
2,371,951 |
18,939,048 |
| Proposal 2. |
Ratification and approval of the appointment of PricewaterhouseCoopers LLP as the Company’s registered independent public accounting firm for the fiscal year ending December 31, 2017. |
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| 25,199,185 |
288,746 |
347,191 |
– |
| Proposal 3. |
Approval of an advisory vote to approve, on an advisory basis, the compensation of the Company’s named executive officers. |
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| 5,893,984 |
737,235 |
264,855 |
18,939,048 |
About Repros Therapeutics Inc. (NASDAQ:RPRX)
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.